Evorpacept improved tumor response in patients with HER2-positive gastric/GEJ cancer, becoming the first ... TRP to an assumed RP control ORR of 30% Secondary endpoints of PFS and OS were immature ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Overall survival (OS) data, a secondary ... Cancer Institute on Unsplash. Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment ... it can be accessed via the Cancer Drugs Fund – but covered ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Nov. 11, 2024 — A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer ... DNA Packaging Directly Affects How Fast ...

small secondary cancers might be clinically irrelevant if the index lesion is treated The future success of focal therapy will depend on adequate prostate sampling at biopsy, along with accurate ...

GenesisCare, the UK’s leading private cancer care provider, has launched a thought-provoking photography exhibition to raise awareness of where secondary breast cancer might occur in the body at its ...

Any chemotherapy, of course, comes with [adverse] effects and can increase the long-term risk of secondary cancers. Now, we have transitioned to being entirely chemotherapy free. Most of our frontline ...